Early Detection of Cardiac Involvement in Systemic Sclerosis Assessed by Tissue-Doppler Echocardiography: Relationship with Neurohormonal Activation and Endothelial Dysfunction

Objective. Cardiopulmonary complications are common in patients with systemic sclerosis (SSc). We assessed cardiac involvement in patients with SSc using echocardiography and investigated the association of N-terminal pro-brain natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) with echocardiographic measures of myocardial function in sera of patients with SSc who had no symptoms of heart failure. Methods. We prospectively studied 52 patients with SSc (mean age 55.7 ± 10.1 yrs, 51 women), with conventional and tissue-Doppler echocardiography. Plasma NT-proBNP and ADMA levels were measured in all patients. Data were compared with those obtained from 25 healthy controls comparable for age and sex. Results. Patients with SSc had impaired left ventricular (LV) and right ventricular diastolic function expressed by inverted ratio of peak early to peak late transmitral (Mit E/A) and transtricuspid velocity and increased left atrial diameter compared with controls. Peak systolic mitral lateral annular motion velocity and peak early diastolic mitral lateral annular motion velocity (LV Em) were lower, while LV E/Em ratio was higher, in patients with SSc compared to controls. ADMA was significantly related with LV Em and E/Em ratio. NT-proBNP was associated with Mit E, Mit E/A ratio and mitral deceleration time. Significant correlation was also observed between NT-proBNP and ADMA levels. Conclusion. Depressed cardiac function is common, even in asymptomatic patients with SSc. NT-proBNP and ADMA are significantly correlated with echocardiographic abnormalities, providing a potent link for cardiac function, neuroendocrine derangement, and endothelial dysfunction in patients with SSc who have cardiac disease.

[1]  G. Giannakoulas,et al.  Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. , 2010, Seminars in arthritis and rheumatism.

[2]  E. Schwedhelm,et al.  Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. , 2009, Pharmacological research.

[3]  D. Dumitrascu,et al.  Systolic and diastolic function in patients with systemic sclerosis. , 2009, European journal of internal medicine.

[4]  D. Farge,et al.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.

[5]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? , 2008, Annals of the rheumatic diseases.

[6]  Y. Allanore,et al.  Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies , 2008, Current opinion in rheumatology.

[7]  G. Giannakoulas,et al.  Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. , 2008, Rheumatology.

[8]  S. Hazen,et al.  Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. , 2008, European heart journal.

[9]  L. Mouthon,et al.  Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. , 2008, Arthritis and rheumatism.

[10]  Alan C. Wilson,et al.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. , 2008, The Journal of rheumatology.

[11]  R. Naeije,et al.  Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? , 2007, European Respiratory Journal.

[12]  G. Giannakoulas,et al.  Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2007, International Journal of Cardiology.

[13]  M. Wolzt,et al.  Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart Failure , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[15]  W. März,et al.  Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.

[16]  M. Humbert,et al.  Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis , 2007, Annals of the rheumatic diseases.

[17]  M. Kurzyna,et al.  Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis , 2006, Clinical Rheumatology.

[18]  M. Wolzt,et al.  Asymmetric Dimethylarginine Predicts Major Adverse Cardiovascular Events in Patients With Advanced Peripheral Artery Disease , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Y. Allanore,et al.  Primary myocardial involvement in systemic sclerosis. , 2006, Rheumatology.

[20]  C. Black,et al.  Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. , 2006, Rheumatology.

[21]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[22]  Chun-Peng Liu,et al.  Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[23]  M. Emdin,et al.  Heart involvement and systemic sclerosis , 2005, Lupus.

[24]  S. Rantapää-Dahlqvist,et al.  Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. , 2005, Chest.

[25]  F. Manguso,et al.  Echocardiographic alterations in systemic sclerosis: a longitudinal study. , 2005, Seminars in arthritis and rheumatism.

[26]  A. Holmes,et al.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.

[27]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[28]  S. Kimmel,et al.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.

[29]  G. Valentini,et al.  Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension , 2000, Annals of the rheumatic diseases.

[30]  A. Takeshita,et al.  Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. , 1998, Hypertension.

[31]  A J Tajik,et al.  Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. , 1996, Journal of the American College of Cardiology.

[32]  G. Nuki,et al.  Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. , 1996, British Journal of Rheumatology.

[33]  N. Schiller,et al.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. , 1990, The American journal of cardiology.

[34]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[35]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[36]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[37]  M. Raza.  High N-Terminal Pro–Brain Natriuretic Peptide Levels and Low Diffusing Capacity for Carbon Monoxide as Independent Predictors of the Occurrence of Precapillary Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis , 2009 .

[38]  D. Borderie,et al.  High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. , 2008, Arthritis and rheumatism.

[39]  M. Emdin,et al.  Assessment of heart involvement. , 2003, Clinical and experimental rheumatology.